Compare Novartis AG (NVS) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Roblox Corp — how do they compare? Novartis AG trades at $152.89 (market cap $295.37B), while Roblox Corp trades at $35.49 (market cap $25.87B). The key difference: Novartis AG is far larger — about 11.4× Roblox Corp's market cap, and Novartis AG pays a 3.07% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| NVS | RBLX | |
|---|---|---|
Market Cap | $295.37B | $25.87B |
Sector | Health | Media |
52-Week High | $168.62 | $141.56 |
52-Week Low | $119.31 | $35.60 |
Enterprise Value | $336.69B | $24.70B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Roblox (RBLX) trades at $35.33, down 4.64% on the day, amid a bearish technical signal and negative investor sentiment driven by multiple class-action lawsuits. The company shows strong revenue growth, with 2025 revenue reaching $4.89 billion, but remains unprofitable with a net income margin of -17.61%. Recent earnings have beaten expectations, yet management withdrew full-year 2026 guidance, increasing uncertainty.
The outlook is mixed: robust user engagement and revenue growth offer long-term potential, but near-term risks from legal challenges and persistent losses warrant caution. Analyst consensus is a Buy with a $45.67 price target, suggesting upside if execution improves, though volatility from negative news flow may pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
